| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.21 | 0.0001 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.15 | 0.009 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.1 | 0.03 |